BridgeBio Pharma, Inc.

BBIO Net selling

CIK 0001743881 #743 in the set updated 17 Sep 2026

Bought (120 mo)

$210.30M

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$1.44B

$160.91M on a plan · $57.95M straight out of an exercise

Sold at will

$1.22B

146 of 428 sales

Net

−$1.23B

−$1.01B against sales at will

By person

28 insiders · 454 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

KKR Genetic Disorder L.P.

10% owner

$45.00M (1)

$840.72M (5)

−$795.72M

13,260,971

6.78%

$1.14B

—

VIKING GLOBAL INVESTORS LP entity

10% owner

$80.00M (1)

$313.49M (3)

−$233.49M

18,555,375

9.49%

$1.59B

—

Kumar Neil

Chief Executive Officer

—

$148.80M (214) scheduled

−$148.80M

749,013

0.3832%

$64.15M

—

VIKING GLOBAL PERFORMANCE LLC entity

10% owner

$80.00M (1)

—

+$80.00M

26,620,991

13.62%

$2.28B

—

MCCORMICK FRANK

Director

—

$33.91M (22) scheduled

−$33.91M

690,558

0.3532%

$59.15M

—

Cook Jennifer E.

Director

—

$21.92M (6) scheduled

−$21.92M

8,383

0.0043%

$718.00K

—

HOMCY CHARLES J

Director

—

$19.45M (10) scheduled

−$19.45M

919,876

0.4706%

$78.79M

+11,522%

Lo Andrew

Director

$98.85K (2)

$10.17M (5)

−$10.07M

68,662

0.0351%

$5.88M

−72.1%

STEPHENSON BRIAN C

CFO and Treasurer

$1.44M (2)

$11.31M (47) scheduled

−$9.87M

102,464

0.0524%

$8.78M

+2,112%

SCHELLER RICHARD H

Director

—

$9.47M (8)

−$9.47M

53,822

0.0275%

$4.61M

—

Ellis Andrea

Director

$100.68K (1)

$7.87M (5) scheduled

−$7.77M

22,579

0.0116%

$1.93M

—

Trimarchi Thomas

President and CFO

—

$5.99M (9) scheduled

−$5.99M

336,529

0.1721%

$28.82M

−14.8%

Valantine Hannah

Director

$69.58K (3)

$5.58M (16) scheduled

−$5.51M

9,657

0.0049%

$827.12K

+1,132%

DANIELS RONALD J

Director

$298.68K (2)

$4.04M (2) scheduled

−$3.74M

20,981

0.0107%

$1.80M

—

HENDERSON MICHAEL THOMAS

Chief Business Officer

$119.00K (1)

$3.75M (35) scheduled

−$3.64M

274,211

0.1403%

$23.49M

+17,299%

Turtle Cameron

See Remarks

—

$3.63M (17) scheduled

−$3.63M

12,568

0.0064%

$1.08M

—

Scott Randal W.

Director

$1.00M (1)

$2.48M (17) scheduled

−$1.48M

15,589

0.0080%

$1.34M

+211.8%

MOMTAZEE JAMES C

Director

$1.16M (1)

—

+$1.16M

19,070

0.0098%

$1.63M

—

Apuli Maricel

Chief Accounting Officer

—

$706.65K (7) scheduled

−$706.65K

122,687

0.0628%

$10.51M

−2.3%

Hassan Fred

Director

$273.39K (1)

—

+$273.39K

29,879

0.0153%

$2.56M

—

SAUNDERS BRENT L

Director

$254.88K (1)

—

+$254.88K

17,600

0.0090%

$1.51M

—

Dachille Douglas A.

Director

$245.58K (3)

—

+$245.58K

30,579

0.0156%

$2.62M

—

Sinha Uma

Chief Scientific Officer

$238.00K (1)

—

+$238.00K

16,460

0.0084%

$1.41M

—

Satvat Ali J.

Director

—

—

—

169,983

0.0870%

$14.56M

—

Stolz Brian M.

Chief Operating Officer

—

—

—

24,615

0.0126%

$2.11M

+3,258%

AGUIAR ERIC

Director

—

—

—

10,579

0.0054%

$906.09K

—

YAU YI CHING

Chief Accounting Officer

—

—

—

4,586

0.0023%

$392.79K

+525.6%

KKR Management Holdings L.P. entity

10% owner

—

—

—

0

0.0000%

$0.00

−100.0%

Individual transactions

0

Nothing of that kind in this period.

What was left out

Form 4 filings counted 400

Amendments (4/A) skipped 5

Filings about a different issuer 8

Unreadable filings 0

Joint filings 12

Sales on a Rule 10b5-1 plan 209

Sales straight out of an exercise 73

Sales at will 146

Transactions with no price 1

Shares from compensation/vesting 141,557,600

Sales filed before the plan box existed 128

History held since 26 Jun 2018